Literature DB >> 29637449

Healthcare resources utilisation in primary progressive multiple sclerosis.

Carlo Piccinni1, Giulia Ronconi2, Silvia Calabria2, Letizia Dondi2, Emanuele Forcesi2, Elisa Rossi3, Antonella Pedrini2, Nello Martini2.   

Abstract

Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This study was aimed to evaluate the burden of PPMS in Italy with healthcare resources utilisation and costs for Italian National Health System (INHS). A 2-year cross-sectional analysis of real-world data collected in the ARCO database, covering > 10 million Italian inhabitants, was performed. From a cohort of patients affected by MS in 2014, those supposedly affected by PPMS were defined by the concurrent matching of absence of disease-modifying treatments and use of rehabilitation services. Any other drug prescriptions, outpatient services and hospitalisations were analysed in 2015 for each subject. The average annual cost per patient was provided both for each expenditure item and by integrating these. Of 13,253,591 inhabitants, 18,453 resulted affected by MS (prevalence 139 × 100,000). Of these, 1849 agreed with additional criteria to identify PPMS (10% of MS population). The 26.8% of these experienced at least one admission in 1 year, 97.3% used at least one outpatient service and 94.3% received at least one reimbursed drug. In the perspective of INHS, PPMS generated an average annual cost of € 3783 per person: 49% for hospitalisations, 28% for outpatient services and 23% for drugs. This study provides a reliable estimation of the PPMS burden in Italy, in terms of healthcare utilisation and direct costs. These findings could be useful to estimate the changes in health expenditure following the incoming of new drugs to treat PPMS with increase of pharmaceutical cost and potential decrease of rehabilitation and hospitalisation costs.

Entities:  

Keywords:  Administrative databases; Burden of disease; Italy; Primary progressive multiple sclerosis; Real-world evidence

Mesh:

Year:  2018        PMID: 29637449     DOI: 10.1007/s10072-018-3404-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  24 in total

1.  Prevalence of Multiple Sclerosis in Tuscany (Central Italy): A Study Based on Validated Administrative Data.

Authors:  Daiana Bezzini; Laura Policardo; Giuseppe Meucci; Monica Ulivelli; Sabina Bartalini; Francesco Profili; Mario Alberto Battaglia; Paolo Francesconi
Journal:  Neuroepidemiology       Date:  2015-12-01       Impact factor: 3.282

2.  Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community.

Authors:  Nancy J Holland; Diana M Schneider; Robert Rapp; Rosalind C Kalb
Journal:  Int J MS Care       Date:  2011

3.  New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.

Authors:  Mario Battaglia; Gisela Kobelt; Michela Ponzio; Jenny Berg; Daniela Capsa; Johan Dalén
Journal:  Mult Scler       Date:  2017-08       Impact factor: 6.312

4.  Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.

Authors:  Paul Browne; Dhia Chandraratna; Ceri Angood; Helen Tremlett; Chris Baker; Bruce V Taylor; Alan J Thompson
Journal:  Neurology       Date:  2014-09-09       Impact factor: 9.910

5.  New Inroads Against Multiple Sclerosis.

Authors:  Jeff Lyon
Journal:  JAMA       Date:  2018-01-02       Impact factor: 56.272

6.  Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors:  Jerry S Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

7.  Costs and quality of life of multiple sclerosis in Italy.

Authors:  Gisela Kobelt; Jenny Berg; Peter Lindgren; M Battaglia; C Lucioni; A Uccelli
Journal:  Eur J Health Econ       Date:  2006-09

8.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

9.  Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs.

Authors:  Michela Ponzio; Simone Gerzeli; Giampaolo Brichetto; Daiana Bezzini; Gian Luigi Mancardi; Paola Zaratin; Mario Alberto Battaglia
Journal:  Neurol Sci       Date:  2014-08-11       Impact factor: 3.307

10.  Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis.

Authors:  S Calabria; E Cinconze; M Rossini; E Rossi; A P Maggioni; A Pedrini; M De Rosa
Journal:  Patient Prefer Adherence       Date:  2016-04-19       Impact factor: 2.711

View more
  2 in total

1.  HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.

Authors:  Carlo Piccinni; Letizia Dondi; Giulia Ronconi; Silvia Calabria; Antonella Pedrini; Immacolata Esposito; Nello Martini; Maurizio Marangolo
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

2.  Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Authors:  Marita Zimmermann; Elizabeth Brouwer; Jeffrey A Tice; Matt Seidner; Anne M Loos; Shanshan Liu; Richard H Chapman; Varun Kumar; Josh J Carlson
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.